Please enable JavaScript or talk to your local administrator to get JavaScript enabled.



Funder: National Cancer Institute

Funding period
USD 2.0 M
Funding amount
PROJECT SUMMARY/ABSTRACT . Bladder cancer is a leading cause of death in the US and the most expensive cancer to treat. Despite this, there has been only one new bladder cancer therapy, the checkpoint inhibitor atezoluzimab, approved in the past 30 years. Oncolytic viruses, viruses that selectively infect and kill cancer cells, are a potent new class of immunotherapy that mediate anticancer activity by direct virus induced killing and robust activation of immune responses against tumor associated antigens. Vyriad's lead oncolytic measles virus product, MV-NIS, has shown clinical safety and efficacy following intravenous and intraperitoneal treatment in patients with advanced multiple myeloma and ovarian cancer respectively and potently kills bladder cancer cell lines in in vitro studies. Our goal is to develop oncolytic MV-NIS as a new treatment for bladder cancer, a malignancy that has demonstrated susceptibility to immunotherapy. A majority of patients are diagnosed with non-muscle invasive disease (NMIBC), of which approximately 50% of patients fail first line therapy. These patients, and patients with muscle invasive disease (MIBC), have no effective therapeutic options and facing the likelihood of disease progression or metastasis,often undergo radical cystectomy (complete bladder removal) which significantly impacts quality of life. In this SBIR fast-track application we propose to (I) confirm feasibility and identify optimal conditions for intravesical administration of MV-NIS and (II) carry out a Phase 1 clinical trial to evaluate intravesical MV-NIS therapy in patients scheduled to undergo radical cystectomy. This study will provide the critical demonstration of feasibility and safety of intravesical MV-NIS administration, as well preliminary indication of therapeutic efficacy to inform the decision to advance MV-NIS therapy in a pivotal clinical trial to seek approval as a novel bladder cancer therapy. We utilize an innovative clinical trial design that allows correlative analysis to define mechanism of action of MV-NIS therapy including characterization of antitumor immune responses. This will inform future studies to combine MV-NIS therapy with approved checkpoint inhibitors to potentially develop a more potent therapeutic approach for patients with locally advanced or metastatic bladder cancer. We are bringing together Vyriad's team, leading experts in oncolytic virotherapy development, with Mayo Clinic's nationally number one ranked Urology department, to perform this study that will, if successful, lead to the approval of a new, much-needed treatment for bladder cancer patients.
Similar projects All >
Sorted by: Start Date
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
Bladder cancer chemotherapy potentiation with a multiprong arachidonic acid pathway modulator

National Cancer Institute to PAUL THOMAS HENDERSON

USD 300,000
2019 - 2020
Project list item
Geriatric Conditions and Treatment Burden in Older Adults with Non-Muscle-Invasive Bladder Cancer and Their Caregivers

National Institute on Aging to TULLIKA GARG

USD 135,849
2019 - 2021
Project list item
Developing a SMART scaffold for bladder augmentation

National Institute of Biomedical Imaging and Bioengineering to GUILLERMO ANTONIO AMEER, ARUN SHARMA, JOHN ROGERS

USD 709,004
2019 - 2023
Project list item
Investigating underlying molecular mechanisms of epigenetic therapies in muscle-invasive bladder cancer

Bladder Cancer Advocacy Network to Swathi Ramakrishnan

USD 1,700
2019 - 2019



    1112 Oncology and Carcinogenesis

  • RCDC

    Gene Therapy

  • RCDC


  • RCDC

    Clinical Research

  • RCDC

    Clinical Trials and Supportive Activities

  • RCDC


  • RCDC

    Orphan Drug

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases




    5.1 Pharmaceuticals


    6.1 Pharmaceuticals

  • Health Research Areas


  • Broad Research Areas

    Clinical Medicine and Science